Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike,Cell

当前位置： X-MOL 学术 › Cell › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Cell ( IF 45.5 ) Pub Date : 2022-05-02 , DOI: 10.1016/j.cell.2022.04.035
Daichi Yamasoba ₁ , Izumi Kimura ₂ , Hesham Nasser ₃ , Yuhei Morioka ₄ , Naganori Nao ₅ , Jumpei Ito ₂ , Keiya Uriu ₆ , Masumi Tsuda ₇ , Jiri Zahradnik ₈ , Kotaro Shirakawa ₉ , Rigel Suzuki ₄ , Mai Kishimoto ₁₀ , Yusuke Kosugi ₁₁ , Kouji Kobiyama ₁₂ , Teppei Hara ₁₃ , Mako Toyoda ₁₄ , Yuri L Tanaka ₁₅ , Erika P Butlertanaka ₁₅ , Ryo Shimizu ₁₆ , Hayato Ito ₄ , Lei Wang ₇ , Yoshitaka Oda ₁₇ , Yasuko Orba ₁₈ , Michihito Sasaki ₁₉ , Kayoko Nagata ₉ , Kumiko Yoshimatsu ₂₀ , Hiroyuki Asakura ₂₁ , Mami Nagashima ₂₁ , Kenji Sadamasu ₂₁ , Kazuhisa Yoshimura ₂₁ , Jin Kuramochi ₂₂ , Motoaki Seki ₂₃ , Ryoji Fujiki ₂₃ , Atsushi Kaneda ₂₃ , Tadanaga Shimada ₂₄ , Taka-Aki Nakada ₂₄ , Seiichiro Sakao ₂₅ , Takuji Suzuki ₂₅ , Takamasa Ueno ₁₄ , Akifumi Takaori-Kondo ₉ , Ken J Ishii ₁₂ , Gideon Schreiber ₈ , , Hirofumi Sawa ₂₆ , Akatsuki Saito ₂₇ , Takashi Irie ₂₈ , Shinya Tanaka ₇ , Keita Matsuno ₂₉ , Takasuke Fukuhara ₄ , Terumasa Ikeda ₁₆ , Kei Sato ₃₀

Affiliation

Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Faculty of Medicine, Kobe University, Kobe, Japan.
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan; Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan.
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan; Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, Japan.
Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan.
Tokyo Metropolitan Institute of Public Health, Tokyo, Japan.
Interpark Kuramochi Clinic, Utsunomiya, Japan.
Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Department of Emergency and Critical Care Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan; Center for Animal Disease Control, University of Miyazaki, Chiba, Japan; Graduate School of Medicine and Veterinary Medicine, University of Miyazaki, Miyazaki, Japan.
Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
One Health Research Center, Hokkaido University, Sapporo, Japan; International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan; Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan.

Soon after the emergence and global spread of the SARS-CoV-2 Omicron lineage BA.1, another Omicron lineage, BA.2, began outcompeting BA.1. The results of statistical analysis showed that the effective reproduction number of BA.2 is 1.4-fold higher than that of BA.1. Neutralization experiments revealed that immunity induced by COVID vaccines widely administered to human populations is not effective against BA.2, similar to BA.1, and that the antigenicity of BA.2 is notably different from that of BA.1. Cell culture experiments showed that the BA.2 spike confers higher replication efficacy in human nasal epithelial cells and is more efficient in mediating syncytia formation than the BA.1 spike. Furthermore, infection experiments using hamsters indicated that the BA.2 spike-bearing virus is more pathogenic than the BA.1 spike-bearing virus. Altogether, the results of our multiscale investigations suggest that the risk of BA.2 to global health is potentially higher than that of BA.1.

中文翻译：

SARS-CoV-2 Omicron BA.2 刺突的病毒学特征

在 SARS-CoV-2 Omicron 谱系 BA.1 出现并在全球传播后不久，另一个 Omicron 谱系 BA.2 开始与 BA.1 展开竞争。统计分析结果表明，BA.2的有效繁殖数比BA.1高1.4倍。中和实验表明，广泛应用于人群的 COVID 疫苗诱导的免疫力对 BA.2 无效，类似于 BA.1，并且 BA.2 的抗原性与 BA.1 的抗原性明显不同。细胞培养实验表明，与 BA.1 刺突相比，BA.2 刺突在人鼻上皮细胞中具有更高的复制效率，并且在介导合胞体形成方面更有效。此外，使用仓鼠进行的感染实验表明，BA.2 刺突病毒比 BA.1 刺突病毒更具致病性。共，

更新日期：2022-05-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11